Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10571MR)

This product GTTS-WQ10571MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10571MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10519MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ3310MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ12892MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA OPRX-106
GTTS-WQ10813MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA M7824
GTTS-WQ6809MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ3247MR IVTScrip™ mRNA-Anti-FCGRT, ARGX-113(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ARGX-113
GTTS-WQ5299MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ13089MR IVTScrip™ mRNA-Anti-MADCAM1, PF-00547659(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-00547659
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW